Boston-based Vertex Pharmaceuticals will no longer sell or distribute its Incivek hepatitis C treatment, largely due to newly available drugs such as Gilead's Sovaldi, according to a Reuters report.
Incivek will not be available for patients after Oct. 14. While the drug will no longer be in the hepatitis C treatment market, the company has not indicated when it would stop making the drug, according to the report.
More articles on Sovaldi:
Despite price, Sovaldi still treatment of choice for Hep C
Sovaldi generates $3.48B in Q2 sales
60% of Americans Are Worried They Won't Be Able to Afford Specialty Drugs